AI Portfolio Summary
In 2026 Q1, GILEAD SCIENCES, INC. maintained a portfolio of 6 distinct positions. The fund also reduced its exposure to Xilio Therapeutics I by 92.9%.
Total Positions
6
Quarter
2026 Q1
Top Holding
ACLX (36.4%)
Top 10 Concentration
100.0%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-6 of 6
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
ACLX
Arcellx Inc
|
Healthcare | 36.44% | 22.64% |
#1
2
Prev: #3
|
7.0 | no change | no change |
P
S
|
6,720,803 | $771,682,600 |
$76.69
+49.7%
|
2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-08 | ||
|
RCUS
Arcus Bioscienc...
|
Healthcare | 32.05% | 38.69% |
#2
1
Prev: #1
|
6.5 | no change | no change |
P
S
|
31,424,760 | $678,774,816 |
$14.58
+57.4%
|
2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-08 | ||
|
GLPG
Galapagos NV
|
Healthcare | 23.67% | 28.45% |
#3
1
Prev: #2
|
6.0 | no change | no change |
P
S
|
16,707,477 | $501,224,310 |
$27.50
+7.0%
|
2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-08 | ||
|
ASMB
Assembly Biosci...
|
Healthcare | 5.90% | 7.92% |
#4
Prev: #4
|
3.9 | no change | no change |
P
S
|
4,505,391 | $125,024,600 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-08 | |||
|
KYTX
Kyverna Therape...
|
Healthcare | 1.68% | 2.00% |
#5
Prev: #5
|
2.2 | no change | no change |
P
S
|
4,126,119 | $35,608,407 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-08 | |||
|
XLO
Xilio Therapeut...
|
Healthcare | 0.26% | 0.30% |
#6
Prev: #6
|
0.1 | -8,455,062 | -92.9% |
P
S
|
650,389 | $5,469,771 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-08 |
Showing 1-6 of 6 holdings